Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM@ASCO
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
I would like to offer to pay the salaries of TSA personnel during this funding impasse that is negatively affecting the lives of so many Americans at airports throughout the country
💻V-I-R-T-U-A-L💻O-P-T-I-O-N💻
If you can’t join in person, we now have a VIRTUAL option for the CLM Consensus Conference!👏🎉
Check out the program! Great talks! Tackling huge issues in the care of pts w/CLM
mdanderson.cloud-cme.com/cou…@hitoen9@IHPBA@EAHPBA@AHPBA@JSHBPS
⭐ E-AHPBA Blue Seal Endorsed Event
We encourage our members to participate - in person or online.
Still time to secure your spot!
@MDAndersonNews#EAHPBAEndorsements
Some debates are quiet - this will not be one of them🥊
Histotripsy for liver tumors: practice-changing or premature adoption? #SSO2026💥
Susanne Warner🤜🤛 @drpeterkingham, refereed by @HopSTranCao
Come watch the debate (and decide for yourself) 👉🏻 tinyurl.com/55upkjsr
Grateful to @timnewhook19 & @VautheyMD for their guidance throughout this project!
Huge thanks also to my friends & colleagues @mateolendoire@Haddad_Antony for their help!
Treating obstructive jaundice
➕minimizing cholangitis ➕ adequate sFLR 🟰 safe resection of pCCA
We are grateful for our MD Anderson community.
Today and always, we appreciate our patients and their families, our dedicated faculty and staff, our volunteers and all who support our mission to end cancer.
Wishing you a peaceful Thanksgiving. #EndCancer
Bariatric surgery was associated with more effective, durable treatment of class II and III obesity at lower costs than #GLP1 receptor agonists.
ja.ma/49H4o1p
ALT Four graphs compare GLP-1 RA and MBS treatments over 24 months. A shows weight in kg, B excess weight, C % weight loss, D % excess weight loss. MBS shows greater weight loss compared to GLP-1 RA in all graphs.
Exciting news! The SSAT Research Committee has successfully published their manuscript, “Global Strategies for the Diffusion of Robotic Surgery,” in the Brazilian Archives of Digestive Surgery. Curious to read more? Check out the full manuscript on PubMed: ow.ly/kqz650XwUq9